Ryan Dellinger

This inventor holds 18 USPTO granted patents and 14 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Chromadex Inc., Elysium Health, Inc., The Queen's University of Belfast. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryan Dellinger. Retrieved from https://idiyas.com/inventor/ryan-dellinger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 26(Granted Patents)

Location History:

Irvine, CA (US) (2014)
Azusa, CA (US) (2018 - 2024)

Company Filing History:

The Queen's University of Belfast

patents

4. 3 out of 16,025

University of California

patents

5. 2 out of 52

University of Valencia

patents

6. 1 out of 2

Fundacion Universidad Catolica De Valencia San Vicente Martir

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433908 - Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development (2025-10-07),

2. 12350283 - Methods and compositions for treating motor neuron diseases (2025-07-08),

3. 12128060 - Nicotinamide riboside for use in treating or preventing liver damage (2024-10-29),

4. 12043616 - Crystalline forms of nicotinamide riboside chloride (2024-07-23),

5. 11730751 - Treating and preventing motor neuron diseases using nicotinamide riboside (2023-08-22),

6. 11629163 - Methods of synthesizing nicotinamide riboside (2023-04-18),

7. 11524022 - Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development (2022-12-13),

8. 11414407 - Crystalline forms of nicotinamide riboside chloride (2022-08-16),

9. 11389468 - Nicotinamide riboside for use in treating or preventing liver damage (2022-07-19),

10. 11129843 - Treating and preventing kidney damage (2021-09-28),

11. 10934322 - B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof (2021-03-02),

12. 10857172 - Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development (2020-12-08),

13. 10280190 - Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions (2019-05-07),

14. 10183036 - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors (2019-01-22),

15. 10039725 - Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene (2018-08-07),

Title: Innovations by Ryan Dellinger: Patents and Contributions to Infant Health

Introduction

Ryan Dellinger, based in Azusa, CA, is an accomplished inventor with a remarkable portfolio of 18 patents. His work primarily focuses on advancements in health-related formulations, particularly in enhancing infant development and treating motor neuron diseases.

Latest Patents

Dellinger's latest patents encompass groundbreaking applications of compounds like nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide. These innovations are aimed at developing infant formula compositions that ensure healthy growth and development. In particular, one of his notable patents details methods for delivering key nutrients in combination with essential vitamins like thiamine, riboflavin, niacin, and pyridoxine to infants in need.

Additionally, Dellinger is pioneering methods and compositions to treat motor neuron diseases, including ALS. His research provides a promising avenue for therapeutic interventions by utilizing a combination of nicotinamide riboside, pterostilbene, and specific PDE inhibitors alongside thiol/cysteine donors.

Career Highlights

Throughout his career, Ryan Dellinger has made significant contributions while working with reputable companies such as Chromadex Inc. and Elysium Health, Inc. His expertise has allowed him to be at the forefront of innovative health solutions that address critical medical needs.

Collaborations

In the course of his career, Dellinger has collaborated with notable colleagues like Mark Morris and Troy Rhonemus. These partnerships have facilitated the advancement of his research and the development of impactful health products.

Conclusion

Ryan Dellinger's inventive spirit and commitment to enhancing health outcomes through innovative methodologies in infant formula and neurological treatment underscore his importance in the field. His achievements in securing 18 patents speak to his dedication and contribution to advancing healthcare technology.

Profile summary based on public USPTO records.